November 13, 2017-ROCHESTER, NY-Bio-Optronics, the makers of the Clinical Conductor Clinical Trial Management System (CTMS), and Complion, the eRegulatory and document management platform for sites, have partnered to integrate their best-in-class solutions to deliver a solution for research organizations.
The companies are building upon their long-standing commitment to meet customer needs and develop innovative solutions to empower investigative sites to run the world’s research. This integration introduces a robust application suite, enabling research organizations to operate efficiently and profitably, while maintaining compliance with 21 CFR Part 11, HIPAA, and Good Clinical Practice (GCP).
Clinical research sites receive the most advanced tools for study management through Clinical Conductor-including finances, recruitment, and participant management-with the added power from Complion for regulatory and document management. By streamlining access to critical study documents and statuses, sites can reduce bottlenecks, improve efficiency, and facilitate more timely and accurate decisions.
“We wanted to partner with the best eRegulatory provider in the business to provide the industry with unparalleled innovations that further complement our powerful CTMS and allow research businesses to maximize their operations and enhance research quality,” said Steve Bailey, VP of Clinical Conductor CTMS.
“Complion’s best-in-class regulatory and document management platform complements the multi-tiered robustness of Clinical Conductor CTMS. This integration is a natural extension as it provides a fuller solution for sites. Our partnership provides a step forward for our joint customers and we look forward to collaborating with Bio-Optronics to support investigative sites and advance research,” said Rick Arlow, Founder and CEO of Complion.
Other integrations from Bio-Optronics have included a multitude of software applications such as EMR, EDC, ePRO. The latest integration with Complion is available now, and all are invited to learn more at MAGI West 2017.
About Complion
Complion’s regulatory and document management platform simplifies the management of trial documentation to ensure site efficiency and improve regulatory compliance. Complion partners with physicians, Health Systems, Academic Medical Centers, and NCI designated Cancer Centers to define institutional standards and streamline research operations.
For more information, please visit http://www.complion.com/ or follow @Complion on Twitter or LinkedIn.
About Bio-Optronics
Bio-Optronics, the creator of Clinical Conductor CTMS, is a software and services company that creates user-focused software and services for healthcare organizations that positively impacts the lives of patients around the world. Clinical Conductor CTMS is an established clinical trial management system designed to help businesses run the world’s research. Utilized by thousands of research organizations worldwide, Clinical Conductor is designed to simplify and standardize complex research processes for businesses managing and conducting clinical trials.
For more information, visit www.bio-optronics.com or follow @BioOptronics on Twitter or LinkedIn.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.